ETx-22，一种新型的神经钙黏蛋白 4 导向抗体药物偶联物，在低神经钙黏蛋白 4 表达的肿瘤中表现出安全性和强大的抗肿瘤活性。
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.
机构信息
Laboratoire d'Oncologie Prédictive, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille Université U105, Institut Paoli-Calmettes, Label "Ligue Contre le Cancer", Marseille, France.
TrGET Platform, Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix Marseille Université U105, Institut Paoli-Calmettes, Marseille, France.
出版信息
Cancer Res Commun. 2024 Nov 1;4(11):2998-3012. doi: 10.1158/2767-9764.CRC-24-0176.
ETx-22, a novel ADC combining a tumor nectin-4-specific antibody and an innovative linker to exatecan, demonstrates significant and durable responses in low-target-expressing tumor models that are resistant to MMAE-based EV and has a better toxicity profile. This new ADC has the potential to benefit additional patient populations beyond its current indication.
ETx-22，一种新型 ADC，将肿瘤 nectin-4 特异性抗体与一种创新的连接子相结合，用于 exatecan，在对基于 MMAE 的 EV 耐药的低靶表达肿瘤模型中显示出显著且持久的反应，且具有更好的毒性特征。这种新的 ADC 有可能使超出其现有适应症的更多患者群体受益。
Zotero 插件